Zentek Receives Approval for Nasdaq Listing
Zentek Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) has secured approval to list its common stock on the Nasdaq Capital Market under the symbol ZTEK. The company will continue trading on the TSX Venture Exchange as ZEN. This strategic move aims to enhance visibility and attract U.S. investors. CEO Greg Fenton indicated that the Nasdaq listing is crucial for increasing trading liquidity and gaining greater exposure to institutional investors. Zentek is known for its innovative healthcare solutions, including its ZenGUARD antimicrobial coating.
- Zentek has received approval for a Nasdaq listing, enhancing its market visibility.
- The move to Nasdaq aims to attract more interest from U.S. investors and institutional investors.
- Zentek's innovative health solutions, like the ZenGUARD antimicrobial coating, position it favorably in the market.
- None.
GUELPH, ON / ACCESSWIRE / March 7, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, today announces that it has received approval to have its common stock listed on the Nasdaq Capital Market ("Nasdaq") under the symbol ZTEK. Zentek's common stock will continue to trade on the TSX Venture Exchange (TSX-V) under the symbol ZEN. The Company is evaluating market conditions and other considerations and will announce the date its shares will commence trading in due course but no later than the 60-day limit as of March 4th.
Greg Fenton, CEO of Zentek, commented, "We believe the move to Nasdaq will be pivotal in generating additional interest and awareness in the U.S. investment community and is reflective of our transition to a global technology company focused on disruptive intellectual property in the areas of healthcare and sustainability. We anticipate this listing will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.com.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek Ltd.
View source version on accesswire.com:
https://www.accesswire.com/691757/Zentek-Receives-Approval-for-Nasdaq-Listing
FAQ
When will Zentek start trading on Nasdaq under the symbol ZTEK?
What are the benefits of Zentek's Nasdaq listing for ZENYF shareholders?
What is Zentek known for in the healthcare sector?
How will the Nasdaq listing affect Zentek's stock performance?
